In human hepatocarcinoma cell lines and aflatoxin-induced liver cancer transgenic animal models, atorvastatin has been shown to block phosphorylation and activation of Myc through HMG-CoA reductase-dependent pathways, thereby inhibiting tumorigenesis and tumor growth [57]. This evidence concerns the gene MYC and liver cancer.